Doxofylline (Standard)

CAT: 0804-HY-B0004R-01Size: 10 mgDry Ice: NoHazardous: No
CAT#:0804-HY-B0004R-01Size:10 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Doxofylline (Standard) is the analytical standard of Doxofylline. This product is intended for research and analytical applications. Doxofylline is an orally active PDE IV inhibitor and A1AR antagonist. Doxofylline reduces inflammation in epithelial cells via inhibiting mitochondrial ROS production and amelioration of multiple cellular pathways (NLRP3-TXNIP inflammasome activation) . Doxophylline can be used in studies of asthma, chronic obstructive pulmonary disease, and bronchospasm[1][2][3].
CAS Number
[69975-86-6]
UNSPSC
12352005
Target
Adenosine Receptor; Phosphodiesterase (PDE) ; Reactive Oxygen Species (ROS) ; Reference Standards
Type
Reference Standards
Related Pathways
GPCR/G Protein; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Others
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/doxofylline-standard.html
Smiles
O=C(N1C)N(C)C2=C(N(CC3OCCO3)C=N2)C1=O
Molecular Formula
C11H14N4O4
Molecular Weight
266.25
References & Citations
[1]Jiao P, et al. The protective effect of doxofylline against lipopolysaccharides (LPS) -induced activation of NLRP3 inflammasome is mediated by SIRT1 in human pulmonary bronchial epithelial cells. Artif Cells Nanomed Biotechnol. 2020 Dec;48 (1) :687-694. |[2]Riffo-Vasquez Y, et al. Doxofylline, a novofylline inhibits lung inflammation induced by lipopolysacharide in the mouse. Pulm Pharmacol Ther. 2014 Apr;27 (2) :170-8.|[3]Shukla D, et al. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2009 Oct;10 (14) :2343-56.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards

Popular Products